ANI Pharmaceuticals (ANIP Quick QuoteANIP - Free Report) reported $227.81 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 53.6%. EPS of $2.04 for the same period compares to $1.34 a year ago.

The reported revenue represents a surprise of +7.81% over the Zacks Consensus Estimate of $211.32 million. With the consensus EPS estimate being $1.74, the EPS surprise was +17.24%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how ANI performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Revenues- Rare Disease and Brands - Cortrophin Gel: $101.85 million compared to the $94.58 million average estimate based on six analysts.
• Net Revenues- Rare Disease and Brands - ILUVIEN and YUTIQ: $16.6 million versus the six-analyst average estimate of $23.24 million.
• Total Net Revenues- Rare Disease: $118.45 million versus $117.82 million estimated by six analysts on average.
• Net Revenues- Generic pharmaceutical products: $94.38 million compared to the $79.3 million average estimate based on five analysts. The reported number represents a change of +20.7% year over year.
• Total Net Revenues- Rare Disease and Brands: $129.13 million compared to the $129.55 million average estimate based on three analysts. The reported number represents a change of +128.8% year over year.
• Total Net Revenues- Generics and Other: $98.69 million versus the three-analyst average estimate of $82.88 million. The reported number represents a year-over-year change of +7.4%.
• Net Revenues- Brands: $10.68 million compared to the $11.98 million average estimate based on three analysts.
• Net Revenues- Royalties and other pharmaceutical services: $4.31 million versus $3.85 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -68.5% change.

View all Key Company Metrics for ANI here>>>

Shares of ANI have returned -0.6% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.